These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24618438)

  • 1. Biomarkers in pancreatic neuroendocrine tumors.
    Theochari MS; Syrigos KN; Saif MW
    JOP; 2014 Mar; 15(2):138-9. PubMed ID: 24618438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors.
    Batukbhai BDO; De Jesus-Acosta A
    Pancreas; 2019 Jan; 48(1):9-21. PubMed ID: 30531241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection.
    Roland CL; Starker LF; Kang Y; Chatterjee D; Estrella J; Rashid A; Katz MH; Aloia TA; Lee JE; Dasari A; Yao JC; Fleming JB
    Surgery; 2017 Mar; 161(3):753-759. PubMed ID: 27816207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers.
    Havasi A; Sur D; Cainap SS; Lungulescu CV; Gavrilas LI; Cainap C; Vlad C; Balacescu O
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SMAD4 haploinsufficiency in small intestinal neuroendocrine tumors.
    Hofving T; Elias E; Rehammar A; Inge L; Altiparmak G; Persson M; Kristiansson E; Johansson ME; Nilsson O; Arvidsson Y
    BMC Cancer; 2021 Jan; 21(1):101. PubMed ID: 33509126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.
    Starzyńska T; Karczmarski J; Paziewska A; Kulecka M; Kuśnierz K; Żeber-Lubecka N; Ambrożkiewicz F; Mikula M; Kos-Kudła B; Ostrowski J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of p27
    Conemans EB; Raicu-Ionita GM; Pieterman CRC; Dreijerink KMA; Dekkers OM; Hermus AR; de Herder WW; Drent ML; van der Horst-Schrivers ANA; Havekes B; Bisschop PH; Offerhaus GJ; Borel Rinkes IHM; Valk GD; Timmers HTM; Vriens MR
    J Endocrinol Invest; 2018 Jun; 41(6):655-661. PubMed ID: 29134609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASO Author Reflections: Pancreatic Neuroendocrine Tumor Recurrence and Survival Predicted by Ki67.
    Nieveen van Dijkum EJM
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):531-532. PubMed ID: 30519760
    [No Abstract]   [Full Text] [Related]  

  • 10. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.
    Klöppel G; La Rosa S
    Virchows Arch; 2018 Mar; 472(3):341-349. PubMed ID: 29134440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers in neuroendocrine tumors.
    Duque M; Modlin IM; Gupta A; Saif MW
    JOP; 2013 Jul; 14(4):372-6. PubMed ID: 23846930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of ATM and cyclin B1 in pancreatic neuroendocrine tumor.
    Shin JU; Lee CH; Lee KT; Lee JK; Lee KH; Kim KM; Kim KM; Park SM; Rhee JC
    Tumour Biol; 2012 Oct; 33(5):1645-51. PubMed ID: 22707287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
    Kim JY; Hong SM
    Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endoplasmic Reticulum Stress in Pancreatic Neuroendocrine Tumors is Linked to Clinicopathological Parameters and Possible Epigenetic Regulations.
    Klieser E; Illig R; Státtner S; Primavesi F; Jáger T; Swierczynski S; Kiesslich T; Kemmerling R; Bollmann C; Di Fazio P; Neureiter D
    Anticancer Res; 2015 Nov; 35(11):6127-36. PubMed ID: 26504039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
    Sadanandam A; Wullschleger S; Lyssiotis CA; Grötzinger C; Barbi S; Bersani S; Körner J; Wafy I; Mafficini A; Lawlor RT; Simbolo M; Asara JM; Bläker H; Cantley LC; Wiedenmann B; Scarpa A; Hanahan D
    Cancer Discov; 2015 Dec; 5(12):1296-313. PubMed ID: 26446169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
    Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
    Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors.
    Miki M; Oono T; Fujimori N; Takaoka T; Kawabe K; Miyasaka Y; Ohtsuka T; Saito D; Nakamura M; Ohkawa Y; Oda Y; Suyama M; Ito T; Ogawa Y
    Cancer Med; 2019 Jul; 8(8):3748-3760. PubMed ID: 31129920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
    Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
    Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
    Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
    Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
    Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
    Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.